Agilent announces the sale of the 30,000th series 1100 liquid chromatography system in less than six years
Agilent Technologies Europe has announced the sale of its 30,000th 1100 series liquid chromatograph (LC) system.
Since its introduction in November 1995, the LC system has been used extensively in the pharmaceutical industry for drug development and quality control analysis and is now finding rapid acceptance in the field of drug discovery and proteomics.
The modular 1100 LC combines advanced validation- and certification-support capabilities with innovative design, manufacturing and support features.
The result is an HPLC that has enabled many laboratories to comply more easily with regulatory standards while reducing ownership costs.
"We are pleased with the market acceptance of this instrument system," said Chris van Ingen, senior vice president and general manager of Agilent's Chemical Analysis Group.
"We expect sales to continue to be robust as more pharmaceutical companies continue ramping up their discovery and proteomic research efforts.
The instrument is also gaining further acceptance for polymer characterisation and for environmental and food monitoring."
